David Grinblatt to Lymphoma, Non-Hodgkin
This is a "connection" page, showing publications David Grinblatt has written about Lymphoma, Non-Hodgkin.
Connection Strength
0.188
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.075
-
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol. 2008 Feb; 140(3):313-9.
Score: 0.063
-
Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy. 2002; 4(3):223-40.
Score: 0.042
-
Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. J Clin Apher. 1999; 14(1):31-4.
Score: 0.008